Loading JYOTHYLAB price...
Peers are the listed companies in the exchange's own industry group: Household Products. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 12 Aug 2026), sales rose 3.0% from a year earlier to Rs 773 cr and profit fell 50.8% to Rs 47.6 cr.
- Sales grew 4 years running (Rs 2,196 cr in FY22 to Rs 2,944 cr in FY26).
- Return on equity stayed above 15% from FY24 to FY26 (lowest 18.1%).
- No borrowings at the FY26 balance sheet.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 20 results, the share rose on 11 and fell on 9, and moved by 3% or more on 8.
Q1 FY27: results filed 12 Aug 2026. The share went from its close on 11 Aug 2026 to its close on 13 Aug 2026 -1.99%.
Of every Rs 100 of sales in FY26, Rs 85 went on running costs, Rs 2.1 on depreciation, Rs 0.2 on interest and Rs 4.0 on tax; Rs 11 was left as profit.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales growthSales against the previous financial year. | - | 13.2% | 10.9% | 3.3% | 3.4% |
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | 11.3% | 12.7% | 17.4% | 17.5% | 15.3% |
| Net marginProfit after everything, per Rs 100 of sales. | 7.2% | 9.6% | 13.4% | 13.0% | 11.3% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | 15.5% | 20.4% | 18.1% | 21.0% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | - | 18.9% | 25.2% | 22.7% | 26.9% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | - | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest coverHow many times operating profit covers the interest bill. Higher is safer. | 17.7x | 23.8x | 103x | 83.8x | 91.2x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 2,252 Cr of assets. Its owners funded 71% of that, with no borrowings.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs 473 Cr, spent Rs 67 Cr on plant and equipment, and cash fell by Rs 25 Cr over the year.
Rs 100 or more means every rupee of reported profit arrived as cash.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| DOMS DOMS Industries Limited | 11,451 cr | 52.8x | 9.4x | 17.3% | 23.5% | 0.07 | 9.3% | +19.3% | 0.17% |
| JYOTHYLAB Jyothy Labs Limited | 6,388 cr | 22.5x | 4.0x | 17.9% | 26.9% | 0.00 | 9.6% | +3.0% | 2.01% |
| NAVNETEDUL Navneet Education Limited | 2,665 cr | 7.1x | 130.5x | - | 21.0% | 0.02 | 24.4% | -0.8% | 0.02% |
| FLAIR Flair Writing Industries Limited | 2,399 cr | 17.2x | 2.1x | 12.4% | 15.8% | 0.03 | 11.1% | - | 0.66% |
| EVEREADY Eveready Industries India Limited | 2,154 cr | 12.1x | 3.5x | 28.6% | 23.9% | 0.29 | 12.0% | +9.0% | 0.51% |
| KOKUYOCMLN Kokuyo Camlin Limited | 732 cr | 33.1x | 2.3x | 6.8% | 10.8% | 0.08 | 2.7% | +0.8% | 0.00% |
| NIPPOBATRY Indo-National Limited | 228 cr | - | 0.8x | -8.4% | -7.1% | 0.11 | -5.7% | -2.8% | 1.64% |
| LINC Linc Limited | 126 cr | 15.9x | 0.5x | 12.3% | 18.5% | 0.02 | 5.8% | +1.4% | 7.10% |
| SUNDARAM Sundaram Multi Pap Limited | 49 cr | 12.9x | 0.5x | 4.3% | 5.0% | 0.22 | 2.7% | +22.0% | 0.00% |
| KSHITIJPOL Kshitij Polyline Limited | 46 cr | 12.8x | 0.7x | 6.0% | 8.3% | 0.28 | 7.5% | - | 0.00% |
| AMBICAAGAR Ambica Agarbathies & Aroma industries Limited | 37 cr | 10.9x | 0.3x | 3.0% | 7.9% | 0.78 | 2.5% | -18.2% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from 11.3% to 15.3% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2026 has paid Rs 3.50 per share, about Rs 2,012 on Rs 1 lakh at today's price. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.